

Artur Jurczyszyn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2296997/publications.pdf>

Version: 2024-02-01

141
papers

3,747
citations

236925

25
h-index

144013

57
g-index

164
all docs

164
docs citations

164
times ranked

4521
citing authors

#	ARTICLE	IF	CITATIONS
1	POEMS Syndrome: Real World Experience in Diagnosis and Systemic Therapy - 108 Patients Multicenter Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, 297-304.	0.4	11
2	Monoclonal gammopathy of ocular significance (MGOS) – a short survey of corneal manifestations and treatment outcomes. <i>Leukemia and Lymphoma</i> , 2022, 63, 984-990.	1.3	3
3	A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479.	2.8	5
4	Therapeutic role of eicosapentaenoic and arachidonic acid in benzo(a) pyrene-induced toxicity in HUVEC endothelial cells. <i>Life Sciences</i> , 2022, 293, 120345.	4.3	3
5	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2022, 107, 774-775.	3.5	2
6	The Key Role of Hepcidin-25 in Anemia in Multiple Myeloma Patients with Renal Impairment. <i>Medicina (Lithuania)</i> , 2022, 58, 417.	2.0	3
7	Extramedullary disease in multiple myeloma: a systematic literature review. <i>Blood Cancer Journal</i> , 2022, 12, 45.	6.2	57
8	Monoclonal gammopathy of renal significance (MGRS): Real-world data on outcomes and prognostic factors. <i>American Journal of Hematology</i> , 2022, 97, 877-884.	4.1	12
9	Transgelin-2 in Multiple Myeloma: A New Marker of Renal Impairment?. <i>Molecules</i> , 2022, 27, 79.	3.8	4
10	Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. <i>Haematologica</i> , 2021, 106, 601-604.	3.5	2
11	Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis. <i>Haematologica</i> , 2021, 106, 1182-1187.	3.5	27
12	Common gene variants within 3' untranslated regions as modulators of multiple myeloma risk and survival. <i>International Journal of Cancer</i> , 2021, 148, 1887-1894.	5.1	3
13	Leukaemia cutis for clinicians, a literature review. <i>Postepy Dermatologii I Alergologii</i> , 2021, 38, 359-365.	0.9	8
14	Suppression of steroid 5 α -reductase type I promotes cellular apoptosis and autophagy via PI3K/Akt/mTOR pathway in multiple myeloma. <i>Cell Death and Disease</i> , 2021, 12, 206.	6.3	13
15	Amyloidosis, extramedullary plasmacytoma and light chain disease: impressive results of daratumumab therapy. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 297-298.	0.4	3
16	Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. <i>British Journal of Haematology</i> , 2021, 194, 496-507.	2.5	67
17	Mortality Following <i>Clostridioides difficile</i> Infection in Europe: A Retrospective Multicenter Case-Control Study. <i>Antibiotics</i> , 2021, 10, 299.	3.7	23
18	Erythropoietin: a story of a discovery with Polish contribution. <i>Polish Archives of Internal Medicine</i> , 2021, 131, 317-319.	0.4	1

#	ARTICLE	IF	CITATIONS
37	Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.	4.1	47
38	Interaction between functional polymorphisms in FCER1A and TLR2 and the severity of atopic dermatitis. <i>Human Immunology</i> , 2020, 81, 709-713.	2.4	5
39	Primary refractory multiple myeloma: a real-world experience with 85 cases. <i>Leukemia and Lymphoma</i> , 2020, 61, 2868-2875.	1.3	6
40	KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. <i>Kidney International</i> , 2020, 98, 1407-1418.	5.2	8
41	Evaluating the Relationship of GDF-15 with Clinical Characteristics, Cardinal Features, and Survival in Multiple Myeloma. <i>Mediators of Inflammation</i> , 2020, 2020, 1-13.	3.0	4
42	KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer. <i>Kidney International</i> , 2020, 98, 1108-1119.	5.2	26
43	Allogeneic hematopoietic cell transplantation for multiple myeloma: A retrospective analysis of the Polish Myeloma Group. <i>Advances in Medical Sciences</i> , 2020, 65, 429-436.	2.1	2
44	P0745URINE TIMP-2 AND IGFBP-7- NEW BIOMARKERS OF KIDNEY INJURY IN MULTIPLE MYELOMA PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
45	Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. <i>Lancet</i> , The, 2020, 396, 1563-1573.	13.7	188
46	Modified Pulsatillae decoction inhibits DSS-induced ulcerative colitis in vitro and in vivo via IL-6/STAT3 pathway. <i>BMC Complementary Medicine and Therapies</i> , 2020, 20, 179.	2.7	11
47	Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2020, 10, 767.	2.8	16
48	New Markers of Renal Failure in Multiple Myeloma and Monoclonal Gammopathies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1652.	2.4	9
49	Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group. <i>Archives of Medical Science</i> , 2020, , .	0.9	1
50	A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma. <i>American Journal of Hematology</i> , 2020, 95, 503-509.	4.1	11
51	Negative Impact of Borderline Creatinine Concentration and Glomerular Filtration Rate at Baseline on the Outcome of Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplant. <i>Transplantation Proceedings</i> , 2020, 52, 2186-2192.	0.6	3
52	Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1885-1893.	1.3	3
53	Plasma Cell Leukemia – Facts and Controversies: More Questions than Answers?. <i>Clinical Hematology International</i> , 2020, 2, 133.	1.7	5
54	Monoclonal gammopathies of undetermined significance and smoldering myeloma. <i>Acta Haematologica Polonica</i> , 2020, 51, 193-202.	0.3	0

#	ARTICLE	IF	CITATIONS
73	Abnormal hemostasis screening tests leading to diagnosis of multiple myeloma. <i>Acta Haematologica Polonica</i> , 2019, 50, 32-35.	0.3	4
74	High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group. <i>Oncology Letters</i> , 2019, 18, 5811-5820.	1.8	4
75	Wyzwania wczesnej diagnostyki szpiczaka plazmocytoowego – algorytm diagnostyczny. <i>Acta Haematologica Polonica</i> , 2019, 50, 121-129.	0.3	0
76	Next-generation immunomodulatory drugs in multiple myeloma. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2019, 73, 791-802.	0.1	0
77	High expression of CC chemokine receptor 5 (CCR5) promotes disease progression in patients with B-cell non-Hodgkin lymphomas. <i>Current Problems in Cancer</i> , 2018, 42, 268-275.	2.0	4
78	Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. <i>British Journal of Haematology</i> , 2018, 180, 831-839.	2.5	41
79	Stem cell mobilization in patients with dialysis-dependent multiple myeloma: Report of the Polish Myeloma Study Group. <i>Journal of Clinical Apheresis</i> , 2018, 33, 249-258.	1.3	3
80	The relationship between plasma renin activity and serum lipid profiles in patients with primary arterial hypertension. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2018, 19, 147032031881002.	1.7	6
81	Quiz What is your diagnosis?. <i>Polish Journal of Pathology</i> , 2018, 69, 107-107.	0.3	0
82	Intraoral manifestation of systemic AL amyloidosis with unique microscopic presentation of intracellular amyloid deposition in striated muscles. <i>Polish Journal of Pathology</i> , 2018, 69, 200-204.	0.3	2
83	Autologous peripheral blood stem cell transplantation in dialysis-dependent multiple myeloma patients – DAUTOS Study of the Polish Myeloma Study Group. <i>European Journal of Haematology</i> , 2018, 101, 475-485.	2.2	11
84	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 183, 375-384.	2.5	11
85	Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study. <i>American Journal of Hematology</i> , 2018, 93, E238-E241.	4.1	6
86	The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a real-world study: Polish Myeloma Group experience. <i>European Journal of Haematology</i> , 2018, 101, 354-361.	2.2	13
87	The Prognostic Impact of t(14;16) in Multiple Myeloma: A Multicenter Retrospective Study of 213 Patients. Is It Time to Revise the Revised ISS?. <i>Blood</i> , 2018, 132, 4452-4452.	1.4	3
88	Blocking MET receptor signaling in multiple myeloma cells in vitro and in vivo. <i>Advances in Clinical and Experimental Medicine</i> , 2018, 27, 153-158.	1.4	1
89	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ...ce rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2018/2019. <i>Acta Haematologica Polonica</i> , 2018, 49, 157-206.	0.3	4
90	The Prognostic Impact of t(14;20) in Multiple Myeloma - a Multicenter Retrospective Study of 26 Patients. <i>Blood</i> , 2018, 132, 5600-5600.	1.4	0

#	ARTICLE	IF	CITATIONS
109	The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective. <i>Oncologist</i> , 2016, 21, 333-342.	3.7	28
110	Cutaneous involvement in multiple myeloma: a multi-institutional retrospective study of 53 patients. <i>Leukemia and Lymphoma</i> , 2016, 57, 2071-2076.	1.3	30
111	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMENSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048.	1.8	16
112	Monoklonalne przeciwciaÅ,a w szpiczaku plazmocytowym â€œ przeÅ,om w terapii. <i>Acta Haematologica Polonica</i> , 2015, 46, 359-367.	0.3	1
113	The Analysis of the Relationship between Multiple Myeloma Cells and Their Microenvironment. <i>Journal of Cancer</i> , 2015, 6, 160-168.	2.5	12
114	Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement. <i>Journal of Clinical Oncology</i> , 2015, 33, 657-664.	1.6	330
115	ZajÄ™cie oÅ,rodkowego ukÅ,adu nerwowego w przebiegu szpiczaka plazmocykowego â€œ opis przypadku i przeglÄ...d literatury. <i>Acta Haematologica Polonica</i> , 2015, 46, 242-247.	0.3	2
116	Docosahexaenoic acid regulates gene expression in HUVEC cells treated with polycyclic aromatic hydrocarbons. <i>Toxicology Letters</i> , 2015, 236, 75-81.	0.8	14
117	Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. <i>Nature Communications</i> , 2015, 6, 7539.	12.8	38
118	n-3 Fatty acids as resolvents of inflammation in the A549 cells. <i>Pharmacological Reports</i> , 2015, 67, 610-615.	3.3	35
119	The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2015, 94, 109-114.	2.2	10
120	Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMENSE consortium. <i>Endocrine-Related Cancer</i> , 2015, 22, 545-559.	3.1	11
121	Plasma fatty acid profile in multiple myeloma patients. <i>Leukemia Research</i> , 2015, 39, 400-405.	0.8	35
122	Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. <i>International Journal of Cancer</i> , 2015, 136, E351-8.	5.1	30
123	Percutaneous Vertebroplasty for Pathological Vertebral Compression Fractures Secondary to Multiple Myeloma â€œ Medium-Term and Long-Term Assessment of Pain Relief and Quality of Life. <i>Advances in Clinical and Experimental Medicine</i> , 2015, 24, 651-656.	1.4	11
124	Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor. <i>Journal of Cancer</i> , 2014, 5, 480-490.	2.5	15
125	HGF, sIL-6R and TGF-Î²₁ Play a Significant Role in the Progression of Multiple Myeloma. <i>Journal of Cancer</i> , 2014, 5, 518-524.	2.5	17
126	Bortezomib for the treatment of multiple myeloma. <i>Expert Review of Hematology</i> , 2014, 7, 173-185.	2.2	17

#	ARTICLE	IF	CITATIONS
127	Case-adjusted bortezomib-based strategy in routine therapy of relapsed/refractory multiple myeloma shown to be highly effectiveâ€”A report by Polish Myeloma Study Group. <i>Leukemia Research</i> , 2014, 38, 788-794.	0.8	4
128	Genetic Variants and Multiple Myeloma Risk: IMMEnSE Validation of the Best Reported Associationsâ€”An Extensive Replication of the Associations from the Candidate Gene Era. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 670-674.	2.5	13
129	Erythrocyte membrane fatty acids in multiple myeloma patients. <i>Leukemia Research</i> , 2014, 38, 1260-1265.	0.8	33
130	Dwu-, trzy- i czterolekowe schematy w leczeniu pierwszoliniowym szpiczaka plazmocytoowego z uwzglÄ™dnieniem efektu w terapii z zastosowaniem bortezomibu. <i>Acta Haematologica Polonica</i> , 2014, 45, 26-34.	0.3	0
131	Rheological properties of erythrocytes in patients infected with <i>Clostridium difficile</i> . <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2014, 68, 1397-1405.	0.1	4
132	Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients. <i>Hematological Oncology</i> , 2013, 31, 41-48.	1.7	39
133	International Myeloma Working Group Recommendations for the Treatment of Multiple Myelomaâ€”Related Bone Disease. <i>Journal of Clinical Oncology</i> , 2013, 31, 2347-2357.	1.6	307
134	ChÄ™niak Hodgkina u osÅ³b w wieku podeszÅ™ym. <i>Acta Haematologica Polonica</i> , 2013, 44, 156-160.	0.3	0
135	Transient cortical blindness after coronary artery angiography. <i>Postepy W Kardiologii Interwencyjnej</i> , 2013, 1, 105-108.	0.2	5
136	Zalecenia Polskiej Grupy Szpiczakowej dotyczÄ™ce rozpoznawania i leczenia szpiczaka plazmocytoowego na rok 2012. <i>Acta Haematologica Polonica</i> , 2012, 43, 7-47.	0.3	5
137	Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. <i>Leukemia</i> , 2012, 26, 149-157.	7.2	664
138	Increased Expression of Pro-Angiogenic and Decreased Expression of Osteogenic Genes by Multipotential Stromal Cells after Stimulation with Myeloma-Derived Microvesicles.. <i>Blood</i> , 2007, 110, 3515-3515.	1.4	0
139	Comparison of Myeloma Cells Killing Efficiency by Geldanamycin and Its Analogs.. <i>Blood</i> , 2006, 108, 5027-5027.	1.4	0
140	C-met Receptor as a Potential Target for the Treatment of Patients with Multiple Myeloma.. <i>Blood</i> , 2005, 106, 3395-3395.	1.4	0
141	Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Myeloma Patients?. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 0, , .	2.5	2